-
公开(公告)号：US20220104936A1
公开(公告)日：2022-04-07
申请号：US17062909
申请日：2020-10-05
Inventor： Craig Alan Cable, II , Glenn R. Sussman , James R. Dennewill , Malik Y. Kahook
IPC: A61F2/16
Abstract: An ophthalmic implant including an IOL with haptics, and drug delivery devices secured to the haptics. The posterior-most extent of the drug delivery device is located anterior to the posterior edge or PCE barrier edge, of the IOL. In other configurations, the drug delivery devices are provided with PCO barrier edges.
-
公开(公告)号：US11280912B2
公开(公告)日：2022-03-22
申请号：US16246177
申请日：2019-01-11
Inventor： Dennis M. Akos , Ryan Blay , Nagaraj Channarayapatna Shivaramaiah
Abstract: Various embodiments of the present technology generally relate to localization of one or more radio frequency interference (RFI) emitters. More specifically some embodiments relate to localization of RFI emitters that interfere with Global Navigation Satellite System (GNSS) receivers by integrating the location estimates of two or more localization techniques. Various embodiments may be used to more accurately estimate an interference source (e.g., an RFI emitter's location) than each localization technique separately.
-
公开(公告)号：US11273127B2
公开(公告)日：2022-03-15
申请号：US16146686
申请日：2018-09-28
Inventor： Theodore Randolph , Robert Garcea
Abstract: Embodiments of the present invention provide for novel compositions and methods for making and using a thermally stable human papilloma virus (HPV) formulation or other stabilized multimeric virus formulation. Certain embodiments concern lyophilizing HPV formulations in the presence or absence of adjuvants. Other embodiments concern lypophilizing HPV capsomere vaccines in order to increase stability of an immunogenic composition against HPV infection for storage, delivery and use. In yet other embodiments, a single immunogenic composition can include a thermally stable formulation of multiple virus serotypes. Yet other embodiments disclosed herein concern multi-targeted antigen complexes lyophilized in formulations of use to prolong stability and/or enhance immunogenicity. Other embodiments concern exposing lyophilized multi-targeted antigen complexes to elevated temperatures to enhance immunogenicity of the antigens of the complex to multiple pathogens.
-
114.发明申请公开(公告)号：US20220019020A1
公开(公告)日：2022-01-20
申请号：US17232677
申请日：2021-04-16
Inventor： Milos A. Popovic
Abstract: A grating coupler couples a waveguide to a beam and is formed of patterned shapes in a first and second layer of planar material, the shapes embedded in background material, the layers separated by less than one wavelength. The shapes are organized as a plurality of adjacent unit cells arranged along a direction of propagation of light with each unit cell including a shape of the first material and a shape of the second material, each unit cell having design parameters including a period, a width wb of the shape of first planar material, a width wt of the shape of second planar material, and an offset between the shapes. The coupler has a directivity ratio D is at least 10 dB between “up” and “down” radiation; and unit cells differ in at least one parameter selected from period, wb, wt, and offset to provide a predetermined beam shape.
-
公开(公告)号：US11221334B2
公开(公告)日：2022-01-11
申请号：US16221778
申请日：2018-12-17
Inventor： Jennifer Richer Mouchantat
IPC: G01N33/574 , G01N33/74
Abstract: The present invention provides a method for determining a treatment procedure for breast cancer, a method of predicting a likelihood of success in treating breast cancer, and a method for selecting an endocrine therapy agent for treating breast cancer. In particular, methods of the present invention rely on the amount of androgen receptor (AR) and estrogen receptor (ER) in a tissue sample.
-
Patent Agency Ranking
公开(公告)号：US11219552B2
公开(公告)日：2022-01-11
申请号：US16186030
申请日：2018-11-09
Inventor： Jeffrey Olson
Abstract: An implantable device comprising a substrate capable of capturing an intraocular target molecule and to methods of use thereof. The substrate may be capable of capturing a target molecule present in the eye and/or from fluid of the eye (e.g., an intraocular target molecule). In some embodiments, the substrate has a relatively high affinity for a target molecule.
-
117.发明申请公开(公告)号：US20220000790A1
公开(公告)日：2022-01-06
申请号：US17479395
申请日：2021-09-20
Applicant: The University of North Carolina at Chapel Hill , The Arizona Board of Regents on behalf of the University of Arizona , The Regents of the University of Colorado, a body corporate
Inventor： Paul A. Dayton , Paul S. Sheeran , Terry O. Matsunaga , Mark A. Borden
Abstract: Acoustically activatable particles having low vaporization energy and methods for making and using same are disclosed. A particle of material includes a first substance that includes at least one component that is a gas 25° C. and atmospheric pressure. A second substance, different from the first substance, encapsulates the first substance to create a droplet or emulsion that is stable at room temperature and atmospheric pressure. At least some of the first substance exists in a gaseous phase at the time of encapsulation of the first substance within the second substance to form a bubble. After formation of the bubble, the bubble is condensed into a liquid phase, which causes the bubble to transform into the droplet or emulsion having a core consisting of a liquid. The droplet or emulsion is an activatable phase change agent that remains a droplet having a core consisting of a liquid at 25° C. and atmospheric pressure. The first substance has a boiling point below 25° C. at atmospheric pressure.
-
公开(公告)号：US20210378861A1
公开(公告)日：2021-12-09
申请号：US16893372
申请日：2020-06-04
Inventor： James R. Dennewill , Malik Y. Kahook , Glenn R. Sussman , Craig Alan Cable, II
Abstract: An ophthalmic implant configured for peri-operative, intra-operative, or post-operative assembly and disassembly. Drug delivery devices may be implanted with an intraocular lens, and later removed and replaced with new drug delivery devices.
-
公开(公告)号：US11191851B2
公开(公告)日：2021-12-07
申请号：US16572260
申请日：2019-09-16
Applicant: MUSC Foundation for Research Development , The United States Government as Represented by the Department of Veterans Affairs , The Regents of the University of Colorado, a body corporate , Universitat de Barcelona
Inventor： Stephen Tomlinson , V. Michael Holers , Pablo Engel
IPC: A61K49/00 , A61K51/10 , C07K16/18 , G01N33/569 , A61K49/16 , C07K16/28 , G01N33/534
Abstract: Provided herein, inter alia, are compositions and methods of using the same for detecting complement activation.
-
公开(公告)号：US11187710B2
公开(公告)日：2021-11-30
申请号：US15580968
申请日：2016-06-07
Inventor： Michael P. Chapman
IPC: G01N33/86 , A61B5/02 , G01N11/02 , G01N33/49 , A61B5/00 , G01N11/00 , G16H50/70 , A61B5/15 , A61B5/154
Abstract: In some embodiments, the invention provides an in vitro method for identifying a patient as likely as likely to require a transfusion of at least six units of blood in six hours or less. The method comprise, consists essentially of, or consists of (a) analyzing a sample of blood from a patient with a viscoelastic analysis assay to obtain a coagulation characteristic value that is independent of time of the patient; and (b) comparing the coagulation characteristic value of the patient to a coagulation characteristic value that is independent of time of a control,
wherein the coagulation characteristic value of the patient that is lower than the coagulation characteristic value of the control identifies the patient as likely to require a transfusion of at least six units of blood in six hours or less.
-
-
-
-
-
-
-
-
-
Search Results
1620
records
(took 0.044 seconds)
